|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.21 USD | +0.61% |
|
-12.22% | -19.58% |
| 06-29 | Capricor Therapeutics Gets FDA Advisory Panel Meeting for Duchenne Therapy | MT |
| 06-29 | Capricor Therapeutics, Inc.(NasdaqGS:CAPR) dropped from Russell 3000E Index | CI |
| Market Cap | 1.34B 1.18B 1.08B 1.01B 1.91B 128B 1.94B 12.96B 5.04B 62.91B 5.05B 4.94B 217B | P/E 2026 * |
-39.2x | P/E 2027 * | -35.5x |
|---|---|---|---|---|---|
| Enterprise Value | 1.34B 1.18B 1.08B 1.01B 1.91B 128B 1.94B 12.96B 5.04B 62.91B 5.05B 4.94B 217B | EV / Sales 2026 * |
11.4x | EV / Sales 2027 * | 11x |
| Free-Float |
90.53% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Capricor Therapeutics, Inc.
| 1 day | +0.61% | ||
| 1 week | -12.22% | ||
| Current month | -3.61% | ||
| 1 month | -13.10% | ||
| 3 months | -27.72% | ||
| 6 months | -6.45% | ||
| Current year | -19.58% |
| 1 week | 22.53 |  | 24.99 |
| 1 month | 22.53 | | 30.93 |
| Current year | 21.06 | | 36.82 |
| 1 year | 4.3 | | 40.37 |
| 3 years | 2.68 | | 40.37 |
| 5 years | 2.56 | | 40.37 |
| 10 years | 0.88 | | 44.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 62 | 2013-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 40 | 2017-12-31 |
Michael Binks
CTO | Chief Tech/Sci/R&D Officer | - | 2025-05-12 |
| Director | Title | Age | Since |
|---|---|---|---|
Frank Litvack
CHM | Chairman | 70 | 2013-10-31 |
David Musket
BRD | Director/Board Member | 68 | 2013-11-19 |
George Dunbar
BRD | Director/Board Member | 79 | 2013-11-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-24 | Fiscal year | Chief Financial Officer | 72,300 | 0.1248% | ||
| 06-24 | Fiscal year | General Counsel | 72,300 | 0.1248% | ||
| 06-23 | Fiscal year | General Counsel | 1,200 | 0.0021% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.61% | -12.22% | +126.44% | +416.93% | 1.34B | |
| +0.68% | +5.92% | +77.86% | +136.97% | 59.1B | |
| +2.32% | +5.03% | +75.26% | +92.31% | 55.19B | |
| +3.86% | +6.93% | -11.32% | -10.57% | 24.67B | |
| +4.30% | +7.95% | +14.11% | +440.44% | 24.19B | |
| +1.92% | +8.96% | +53.45% | +0.63% | 19.69B | |
| -0.29% | +9.78% | +43.90% | -29.12% | 17.56B | |
| 0.00% | +20.78% | +186.15% | +347.42% | 16.22B | |
| +6.41% | +22.25% | +51.11% | - | 14.84B | |
| +3.50% | +1.97% | +21.02% | +193.33% | 14.04B | |
| Average | +2.40% | +5.35% | +63.80% | +176.48% | 24.68B | |
| Weighted average by Cap. | +2.26% | +6.31% | +60.30% | +137.91% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 118M 103M 94.86M 88.42M 168M 11.24B 170M 1.14B 443M 5.53B 443M 434M 19.04B | 122M 107M 98.28M 91.61M 174M 11.65B 176M 1.18B 459M 5.73B 459M 449M 19.73B |
| Net income | -28.4M -24.83M -22.82M -21.27M -40.34M -2.7B -40.96M -274M -106M -1.33B -107M -104M -4.58B | -48.17M -42.11M -38.7M -36.07M -68.42M -4.59B -69.45M -465M -181M -2.25B -181M -177M -7.77B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-02 | US$23.21 | +0.61% | 1,641,256 |
| 26-07-01 | US$23.07 | -4.19% | 1,807,652 |
| 26-06-30 | US$24.08 | +1.18% | 1,858,849 |
| 26-06-29 | US$23.80 | -9.98% | 3,243,527 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CAPR Stock
Select your edition
All financial news and data tailored to specific country editions
